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Abstract
Congenital cataract is the most common cause of treatable visual impairment in children worldwide. Mutations in many
different genes lead to congenital cataract. Recently, mutations in the receptor tyrosine kinase gene, EPHA2, have been
found to cause congenital cataract in six different families. Although these findings have established EPHA2 as a causative
gene, the total contribution of mutations in this gene to congenital cataract is unknown. In this study, for the first time, a
population-based approach was used to investigate the frequency of disease causing mutations in the EPHA2 gene in
inherited cataract cases in South-Eastern Australia. A cohort of 84 familial congenital or juvenile cataract index cases was
screened for mutations in the EPHA2 gene by direct sequencing. Novel changes were assessed for segregation with the
disease within the family and in unrelated controls. Microsatellite marker analysis was performed to establish any
relationship between families carrying the same mutation. We report a novel congenital cataract causing mutation
c.1751C.T in the EPHA2 gene and the previously reported splice mutation c.2826-9G.A in two new families. Additionally,
we report a rare variant rs139787163 potentially associated with increased susceptibility to cataract. Thus mutations in
EPHA2 account for 4.7% of inherited cataract cases in South-Eastern Australia. Interestingly, the identified rare variant
provides a link between congenital and age-related cataract.
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Introduction
Cataract is an opacification of the crystalline lens. Congenital
and juvenile cataract form a disease spectrum with presentation
from birth or during early childhood and are generally referred to
as congenital cataract [1]. Congenital cataract is the leading cause
of childhood blindness and accounts for 1–6 and 5–15 cases per
10,000 live births respectively, in developed and poor regions of
developing countries [2,3]. Inherited congenital cataract accounts
for one quarter of the cases [4]. Its genetic heterogeneity is
evidenced by the presence of causative mutations in at least 24
structurally and functionally important genes in the lens, with
mutations in ten crystallin genes accounting for 50% of the known
mutations [4]. Mutations in the EPHA2 gene have been recently
identified to cause congenital cataract [5,6,7,8]. Five different
causative mutations with autosomal dominant mode of inheritance
have been reported each in an American, Australian, British and
two Chinese families [5,6,8]. One mutation with autosomal
recessive mode of inheritance was reported in a Pakistani family
[7]. Age-related cataract, the major cause of blindness in the
elderly, is believed to result from both genetic predisposition and
environmental factors [9]. Synonymous and non-synonymous
variants in the EPHA2 gene have been associated with age-related
cataract in multiple populations [5,10,11,12]. Thus EPHA2 has
been implicated in both congenital and age-related cataract
suggesting a vital role of this gene in lens development and in
maintaining lens cell homeostasis and transparency.
To date, the overall genetic contribution of the EPHA2 gene to
inherited congenital cataract is not known. With this objective, in
the present study, we screened a South-Eastern Australian cohort
of familial cataract cases for causative mutations in the EPHA2
gene. We report a novel causative missense mutation in the gene in
one family and a previously reported splice mutation c.2826-
9G.A [6] in two new families. Additionally, we report a rare non-
synonymous variant in the gene that may be increasing
susceptibility to cataract and, providing a link between congenital
and age-related cataract.
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Materials and Methods
Ethics Statement
Ethics approval for the study was obtained from the Southern
Adelaide Clinical Human Research Ethics Committee, Adelaide,
South Australia, the Royal Victorian Eye and Ear Hospital
(RVEEH) Human Research Ethics Committee, Melbourne,
Victoria, and The University of Sydney and Sydney West Area
Human Research Ethics Committees, New South Wales,
Australia. All participants gave written informed consent. Where
participants were minor or unable to personally provide consent,
written informed consent was obtained from the parent, legal
guardian or an authorized person.
Patient Recruitment
This study attempted to recruit all familial congenital and
juvenile cataract cases in the last 12 years from three states of
South-Eastern Australia, South Australia, Victoria and Tasmania,
and thus approximates a population-based approach in this
region. Probands with familial cataract and their family members
were recruited from the Flinders Medical Centre (Adelaide),
Women’s and Children’s Hospital (Adelaide), Royal Children’s
Hospital (Melbourne) and RVEEH (Melbourne). RVEEH also
served as a tertiary referral centre for patient recruitment from
Tasmania. Family history of the disease in all the families was
available through previous clinical records. Genomic DNA of
recruited individuals was extracted from either whole blood or
saliva or buccal swab using standard methods.
Sequencing Analysis
Probands from 84 families were included in this study. All 17
exons of the EPHA2 gene were amplified by PCR and sequenced
at the Australian Genomic Research Facility (AGRF, Brisbane,
Australia) or in-house by direct sequencing using BigDye
Terminators (Applied Biosystems, Melbourne, Australia) accord-
ing to the standard protocols. Primers used for sequencing are
provided in Tables S1 and S2, respectively. Sequence of EPHA2 in
the probands was compared with the reference sequence
(GenBank accession NM_004431.3) using Sequencher 4.1.0 (Gene
Codes Corporation, Michigan, USA). Novel or potentially disease
causing variants in an individual were assessed for segregation with
the disease by direct sequencing in other available affected and
unaffected family members. The control cohort comprised 270
elderly individuals, with no record of congenital cataract surgery,
recruited from around Adelaide, South Australia, Australia. Out of
these, 66 individuals had age-related cataract. Variant
c.1751C.T in Exon 10 was screened in all the controls using a
custom Taqman assay (Applied Biosystems) on a StepOne Plus
RealTime PCR System (Applied Biosystems). The variant
c.2875G.A in Exon 17 was screened in 218 out of 270 controls,
due to failure of the assay in rest of the controls, using SNaPshot
assay (Applied Biosystems) according to the manufacturer’s
protocols using a probe with sequence- 59-TCC TTG AGT
CCC AGC AGG CTG TAG G- 39. Out of the 218 screened
controls, 58 individuals had age-related cataract. Additionally,
participants from the Blue Mountains Eye Study (BMES) cohort
[13] were screened for this variant. Briefly, the BMES study
recruited individuals 50 years or older, from the Blue Mountains
region, west of Sydney, to investigate ocular diseases in the
Figure 1. The causative mutation in Family 115. a) Pedigree of the Family 115. Solid boxes and circles indicate affected individuals. The
individuals from whom DNA was available have been given a number. The proband is marked with a red arrow. b) Sequence chromatogram showing
the mutation c.1751C.T, marked with an arrow, present in the proband (bottom). The mutation leads to change in a codon, marked by a box,
substituting a proline by a leucine at position 584 in the protein. The translation reading frame is marked with brackets in the normal sequence (top).
c) ClustalW alignment of the region of the human EPHA2 protein including residue 584 showing conservation of the mutated residue across species.
doi:10.1371/journal.pone.0072518.g001
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population. From this cohort, 150 age-related cataract cases, with
unilateral or bilateral cortical cataract, and 271 controls, with no
cataract of any nature, were analyzed for the variant as described
above.
Haplotype Analysis
Haplotype analysis was performed, in the family previously
reported to carry the splice mutation c.2826-9G.A (Family 16)
[6] and the two new families (Family 42 and Family 83) found to
carry the same mutation in this study. Four microsatellite markers
namely D1S228, D1S507, D1S436 and D1S2644 in the telomeric
region of chromosome 1p were typed in affected and unaffected
family members as previously described [14]. Sequences of
primers used for this analysis are provided in Table S3.
Bioinformatics Analysis
Multiple sequence alignment of EPHA2 protein sequences from
human (GenPept accession NP_004422.2), mouse (GenPept
accession NP_034269.2), aquatic frog (GenPept accession
AAH75556.1), rhesus monkey (GenPept accession
NP_001035768.1), chicken (GenPept accession
XP_001234814.2) and zebrafish (GenPept accession
NP_571490.1) was performed using CLUSTALW [15]. Pathoge-
nicity of the novel mutations or variants was predicted using
Sorting Intolerant from Tolerant (SIFT) and Polymorphism
phenotyping v2 (PolyPhen2) online tools [16,17].
Results and Discussion
Previous genetic studies have firmly established involvement of
the EPHA2 gene in development of congenital and age-related
cataract [5,6,7,8,10,11,12]. The EPHA2 gene encodes a 976
amino acid transmembrane tyrosine kinase receptor. The EPHA2
protein has an extracellular region containing the ligand-binding
domain, cysteine-rich domain and two fibronectin domains, a
transmembrane segment, and an intracellular region consisting of
a juxtamembrane domain, tyrosine kinase domain, sterile alpha
motif (SAM) and PDZ domain [18]. EPHA2 interacts with its
ligands, ephrin-A1 or ephrin-A5, to bring about bidirectional
signalling. This signalling plays an important role in cell-adhesion
and cell-repulsion in a context dependent manner [19]. Disruption
of this signalling in the lens is likely the underlying cause of
cataract development. EPHA2 is expressed in human and mouse
lens and co-localises with junctional proteins in lens fibre cells
[10,20]. The Epha2 and ephrin-A5 knockout mice develop
progressive cataracts thus demonstrating the importance of
EPHA2 signalling in maintaining transparency and architecture
of the mammalian lens [10,20,21].
In this study, we aimed to determine genetic contribution of the
EPHA2 gene to inherited congenital cataract in an Australian
cohort. Eighty-four probands with familial congenital or juvenile
cataract, displaying either autosomal dominant or autosomal
recessive mode of inheritance of the disease, were recruited from
South Australia, Victoria and Tasmania. All 17 exons of the
EPHA2 gene were screened for mutations in the probands.
We identified two novel non-synonymous variants, c.493G.A
in probands from Families 41 and 75 and c.2837G.A in the
proband from Family 111. These variants did not segregate with
the disease in these families suggesting that they were not disease
causing changes. They were subsequently listed in dbSNP under
IDs rs150790360 and rs149692543, respectively, following iden-
tification in a large scale exome sequencing project [22].
Furthermore, we identified three potential congenital cataract
causing mutations in Exon 10, Intron 16 and Exon 17 of the
EPHA2 gene segregating with the disease in one or more families.
In Family 115, proband 115-1 presented with bilateral nuclear
lens opacity. A novel mutation, c.1751C.T in Exon 10 of the
gene, was observed (Figure 1). This is a missense mutation,
p.P584L, which alters a highly conserved amino acid in the
juxtamembrane region of the protein (Figure 1). The change was
Figure 2. Congenital cataract in Family 42. a) Pedigree of the Family 42. Solid boxes and circles indicate affected individuals. The individuals
from whom DNA was available have been given a number. The proband is marked with a red arrow. b) Cataract phenotype of 42-12 showing nuclear
cataract.
doi:10.1371/journal.pone.0072518.g002
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predicted to be ‘‘probably damaging’’ using Polyphen2 with a
score of 0.997 (sensitivity: 0.41; specificity: 0.98) and ‘‘not
tolerated’’ using SIFT. Another affected individual from the
family, 115-2, also carried the mutation; which was absent in 270
unrelated controls. This is the first mutation to be identified in the
juxtamembrane region of the protein. Autophosphorylation of
tyrosine residues in this domain of Eph receptors regulates their
activity [23]. Tyrosine residues proximal to the altered proline, at
positions 588 and 594 in human EPHA2, are phosphorylated [24].
Targeted mutation of these tyrosine residues in murine EPHA2
affects receptor interaction with downstream signalling molecules
[25]. Therefore the identified missense mutation may modify
downstream EPHA2 signalling during lens development and lead
to congenital cataract in Family 115.
In Family 42, proband 42-3 presented with bilateral nuclear
lens opacities and 42-12 was subsequently diagnosed with the same
phenotype (Figure 2). We found a splice mutation, c.2826-9G.A
in Intron 16 in the proband, which segregated with the disease in
the family. The same mutation was found in the proband from
Family 83, 83-9, and also segregated with the disease in this family.
Although we do not have any information about the cataract
phenotype of the proband from Family 83, two other affected
family members, 83-1 and 83-3, presented with severe bilateral
nuclear cataracts. The splice mutation found in both the families,
leads to an insertion of 7 bp in the transcript that in turn leads to a
frame-shift and addition of 71 aberrant amino acids in the SAM
domain of the translated protein [6]. This mutation has been
previously reported to cause total congenital cataract in an
Australian family (Family 16) by our group [6]. Therefore to test if
the three families carrying this mutation were related, we
performed haplotype analysis using microsatellite markers span-
ning a distance of approximately 5 Mbp in the region around
EPHA2. The haplotype carrying the mutant-allele was different in
the three families, suggesting that the mutation was an indepen-
dent event in the three families (Figure 3) or these families are
more distantly related than the resolution of the microsatellite
markers could detect. Individual 83-8 from Family 83 carries
different alleles at centromeric marker D1S228 and telomeric
marker D1S2644 than other affected members of the family
(Figure 3) but carries the mutation and the segregating alleles at
Figure 3. Haplotype analysis in Families 16, 83 and 42. Pedigrees of the Families a) 16, b) 83 and c) 42. Solid boxes and circles represent
affected family members. The individuals from whom DNA was available were given a number. Family 83 and 42, from the present study, carry the
same splice mutation c.2826-9G.A as was previously reported in Family 16. Haplotypes of members of each family at microsatellite markers D1S228,
D1S507, D1S436 and D1S2644 are shown. Haplotype carrying the diseased-allele is represented in red and the normal allele in black. The haplotype
carrying the segregating disease allele is different in the three families.
doi:10.1371/journal.pone.0072518.g003
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the two markers closest to EPHA2. A mutation event at marker
D1S228 and a recombination event at D1S2644 could explain
these differences in the distal markers in this patient [26]. Our
results suggest that this mutation, which leads to destabilization of
the protein and reduced migration activity of cells expressing
mutant EPHA2 [27], has occurred multiple times in the South-
Eastern Australian population.
The proband, 74-2, from Family 74 (Figure 4) presented with
bilateral subcapsular and cortical opacities at 17 years of age and
was found to carry a non-synonymous variant, c.2875G.A in
Exon 17 of the gene. This variant leads to a missense change,
p.A959T, in the SAM domain of the protein at a residue that is
highly conserved across species (Figure 4). Another affected family
member, 74-1, presented with bilateral posterior subcapsular
cataract at 20 years of age and carries the same variant. Mutations
Figure 4. The causative mutation in Family 74. a) Pedigree of the Family 74. Solid boxes and circles indicate affected individuals. The individuals
from whom DNA was available have been given a number. The proband is marked with a red arrow. b) Sequence chromatogram showing the variant
c.2875G.A, marked by an arrow, present in the proband (bottom). The variant leads to change in a codon, marked by a box, substituting an alanine
residue by a threonine in the protein at position 959. The translation reading frame is marked with brackets in the normal sequence (top). c) ClustalW
alignment of the region of human EPHA2 including residue 959 showing conservation of the alanine residue across species.
doi:10.1371/journal.pone.0072518.g004
Table 1. Summary of the known congenital cataract causing mutations in the EPHA2 gene.
DNA change Protein change
Location in protein
domain Inheritance Phenotype Reference
c.1751C.T p.P584L Juxtamembrane Dominant Nuclear This study
c.2353G.A p.A785T Tyrosine kinase Recessive Nuclear [7]
c.2668C.T p. R890C Between tyrosine kinase
and SAM domain
Dominant Posterior polar [8]
c.2819C.T p.T940I SAM Dominant Posterior polar [6]
c.2826-9G.A p.D942fs+C71 SAM Dominant Total/nuclear [6] and this study
c.2842G.T p.G948W SAM Dominant Posterior polar [5]
c.2875G.A p.A959T SAM Dominant Subcapsular and
Cortical
This study
c.2915_2916delTG p.V972GfsX39 SAM Dominant Posterior polar [6]
doi:10.1371/journal.pone.0072518.t001
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in SAM domain affect EPHA2 downstream signalling [27] and
therefore this variant may have a functional effect on the protein.
Furthermore, an altered residue at this position can potentially
affect the phosphorylation profile of the adjacent phosphorylated
tyrosine [25]. Consistent with this, the change was predicted to be
‘‘probably damaging’’ using Polyphen2 with a score of 0.995
(sensitivity: 0.68; specificity: 0.97) and as ‘‘not tolerated’’ using
SIFT. Age of diagnosis and cataract phenotype of the affected
individuals in family 74 suggest that the variant led to late-onset
inherited cataract in the family.
This variant was present in 2 out of 218 unrelated South
Australian controls. On further investigation we found that both
these individuals had bilateral age-related cataract. One of them
had anterior cortical cataract in one eye and congenital with
cortical senile cataract in the other eye. This individual had been
known to have cataract of a congenital nuclear pattern for many
years but did not have cataract surgery until 70 years of age
suggesting mild congenital cataract that did not significantly affect
vision. The other individual had developed bilateral cortical
cataract and undergone surgery at 80 years of age. This DNA
change was subsequently listed in dbSNP as rs139787163,
following its identification in the Exome Sequencing Project at a
frequency of 3 alleles in over 10,000 individuals [22]. Therefore to
investigate if the presence of this variant in cataract affected
individuals was coincidental, additional BMES age-related cata-
ract cases and controls were screened but none of them carried the
variant. Therefore the presence of this rare variant only in cataract
affected individuals suggests that it may increase susceptibility to
cataract development, although with varied penetrance, severity
and age of onset. The previously studied synonymous SNP
rs3754334 in Exon 17 of the gene, associated with age-related
cataract in Italian and American populations, is directly adjacent
to this non-synonymous variant [5,10]. This suggests that this
region of the gene may be important in the mechanism of cataract
formation. The spectrum of age of cataract development in
carriers of this variant suggests that cataract is perhaps a
continuous spectrum of disease and the presence of other genetic
and/or environmental factors affects the rate of progression and
severity. This variant provides a link between congenital and age-
related cataract making it an interesting candidate for further
studies.
To date, most of the autosomal dominant congenital cataract
causing mutations in the EPHA2 gene have been reported in the
SAM domain of the protein affecting EPHA2 protein function
(Table 1) [27]. We report the first autosomal dominant mutation
in the juxtamembrane domain of the protein. Interestingly, a
mutation in the SAM domain, one in the tyrosine kinase domain
and the novel mutation in the juxtamembrane region found in this
study, all can lead to nuclear or total cataracts (Table 1) [6,7].
During lens development, the lens nucleus is formed first by the
primary lens fibre cells arising from the posterior lens epithelium,
and then secondary lens fibre cells differentiate from the
epithelium at the lens equator to form the lens cortex that
constitutes the bulk of the lens [28]. Nuclear and total cataract
phenotypes suggest a critical role of EPHA2 in primary fibre cell
formation. In addition, higher expression of EPHA2 in cortical
fibre cells [10,29] and association of SNPs in the gene with age-
related cortical cataract suggest a role of the protein in secondary/
cortical fibre cells, later in life. This is also supported by the fact
that a rare variant in the gene leads to late-onset cortical or
subcapsular cataract in the affected individuals in Family 74. Thus
EPHA2 plays an important role in maintaining lens transparency
throughout life.
In conclusion, this study suggests that mutations in the EPHA2
gene account for approximately 4.7% of inherited cataract cases in
South-Eastern Australia. The frequency of mutations in five
crystallin genes in a subset of this Australian cohort was reported
to be 5.2% [30]. The current study indicates that the frequency of
congenital cataract causing mutations in the EPHA2 gene alone is
comparable to that in the whole group of crystallin genes taken
together. This suggests that mutations in other structurally and
functionally important genes such as EPHA2 in the lens may
contribute a significant proportion of the congenital cataract
burden.
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